Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Tax Provisions (2016 - 2025)

Sangamo Therapeutics has reported Tax Provisions over the past 8 years, most recently at -$553000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 29.51% year-over-year to -$553000.0; the TTM value through Dec 2025 reached -$568000.0, down 240.12%, while the annual FY2025 figure was -$568000.0, 240.12% down from the prior year.
  • Tax Provisions for Q4 2025 was -$553000.0 at Sangamo Therapeutics, down from -$161000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $1.3 million in Q3 2023 and troughed at -$6.3 million in Q2 2023.
  • A 5-year average of -$250850.0 and a median of $78000.0 in 2022 define the central range for Tax Provisions.
  • On a YoY basis, Tax Provisions climbed as much as 4133.33% in 2023 and fell as far as 7739.02% in 2023.
  • Year by year, Tax Provisions stood at -$67000.0 in 2021, then soared by 486.57% to $259000.0 in 2022, then crashed by 205.02% to -$272000.0 in 2023, then plummeted by 56.99% to -$427000.0 in 2024, then decreased by 29.51% to -$553000.0 in 2025.
  • Business Quant data shows Tax Provisions for SGMO at -$553000.0 in Q4 2025, -$161000.0 in Q3 2025, and $27000.0 in Q2 2025.